SCHEMBL2907202

SCHEMBL2907202

CC(C)c1nn(C(C)C)c2c(Nc3ccccc3N)nc(NC3CCCCC3N)nc12

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 4/20 0.44
CDK1 P06493 4/20 0.44
CCNB1 P14635 3/20 0.44
CCNA2 P20248 3/20 0.44
CDK4 P11802 3/20 0.44
CDK5 Q00535 2/20 0.44
CCND1 P24385 1/20 0.44
CDK5R1 Q15078 1/20 0.44
CLK1 P49759 11/20 0.43
CLK2 P49760 11/20 0.43
CLK4 Q9HAZ1 11/20 0.43
CCND3 P30281 2/20 0.43
CCNE1 P24864 3/20 0.42
CCNE2 O96020 2/20 0.42
CCNA1 P78396 2/20 0.42
CLK3 P49761 1/20 0.42
SYK P43405 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905962 0.88 CLK1 (0.49) CDK2CDK1CCNB1CCNA2CDK4
SCHEMBL2906253 0.86 CLK1 (0.46) CDK2CDK1CCNB1CCNA2CDK4
SCHEMBL2908725 0.86 CLK1 (0.53) CDK2CDK1CCNB1CCNA2CDK4
SCHEMBL2910354 0.85 CDK9 (0.44) CDK2CDK1CCNB1CCNA2CDK4
SCHEMBL2912755 0.85 CDK2 (0.50) CDK2CDK1CCNB1CCNA2CDK4
SCHEMBL2910495 0.83 CDK1 (0.44) CDK2CDK1CCNB1CCNA2CDK4
SCHEMBL2914018 0.83 CLK1 (0.49) CDK2CDK1CCNB1CCNA2CDK4
SCHEMBL2914190 0.83 CLK1 (0.48) CDK2CDK1CCNB1CCNA2CDK4
SCHEMBL2937905 0.83 CLK1 (0.48) CDK2CDK1CCNB1CCNA2CDK4
SCHEMBL2905018 0.82 CDK2 (0.64) CDK2CDK1CCNB1CCNA2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1348707-B1 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy USTAV EX BOTAN AV CR V V I I O (CZ) 2010-08-25 EP disclosed
US-7745450-B2 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy INSTITUTE OF EXPERIMENTAL BOTANY (CZ) 2010-06-29 US disclosed
US-20050080097-A1 Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy USTAV EXPERIMENTALNI BOTANIKY AV CR (INSTITUTE OF EXPERIMENTAL BOTANY ACADEMY OF 2005-04-14 US disclosed
EP-1348707-A1 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy Ustav Experimentalni Botaniky AV CR (Institute of Experimental Botany Academy of Sciences of the Czech Republic) (CZ) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080097-A1 Pyrazolo[4,3-D]pyrimidines, processes for their preparation and methods for therapy CBR3, DHFR, AKR1C3 CDK2 685/4885CDK1 1081/4885CCNB1 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.